The researchers sought to determine the type and frequency of hormonal contraceptives and ART prescribed to women with HIV infection and prevalence of resulting drug to drug interaction potential.
Prophylaxis against mycobacterium avium-intracellulare complex (MAC) is recommended for patients with CD4 counts of 3.
The study authors sought to contribute to the evidence base on gender differences in virologic and immunologic responses to ART in treatment-naïve individuals.
Rates of viral failure were compared in HIV patients initiated on dolutegravir-based vs. other guideline recommended regimens in clinical care.
Weight change was assessed over 18 months in patients who switched to an INSTI-containing regimen versus those remaining on EFV/TDF/FTC.
The patients were classified according to the four statin benefit groups from the 2013 ACA/AHA blood cholesterol guidelines.
The patients in the study were placed into 2 groups based on their eGFR at the time of switching agents: the early-switch group (eGFR of ≥60mL/min) and the late-switch group (eGFR <60mL/min).
The exposure-adjusted incidence rate (IR) and relative rate (RR) of both MI and CAD were compared in patients receiving ABC-containing cART to those receiving non ABC-containing cART.
Please login or register first to view this content.
